Some selective inhibitors of nuclear export (SINEs) have been developed initially for cancer therapies, however, recent discoveries have demonstrated that exportin-1 could serve as a target in neurological and neuromuscular disorders containing pathogenic expansion repeats affecting export in protein activity39,43. Here, XPO1 is linked to cancer.